Disease on EC 1.1.1.2 - alcohol dehydrogenase (NADP+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation.
Acidosis
Ethanol metabolism, cirrhosis and alcoholism.
Acute Kidney Injury
Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat.
Changes in 25-hydroxyvitamin D3 alpha- and 24-hydroxylase activities of kidney cells isolated from rats with either unilateral kidney damage or acute renal insufficiency.
Temporal alterations in regional gene expression after nephrotoxic renal injury.
The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice.
Adenocarcinoma
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Albuminuria
Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats.
Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.
Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency.
Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies.
Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus.
alcohol dehydrogenase (nadp+) deficiency
Aldose reductase deficiency improves Wallerian degeneration and nerve regeneration in diabetic thy1-YFP mice.
Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation.
Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma.
Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson's disease.
Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice.
Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice.
Aldose reductase deficiency protects sugar-induced lens opacification in rats.
Aldose reductase deficiency reduced vascular changes in neonatal mouse retina in oxygen-induced retinopathy.
Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgf?1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice.
Alveolar Bone Loss
Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats.
Arthritis
Effect of adjuvant polyarthritis on liver alcohol dehydrogenase in the rat.
Ascorbic Acid Deficiency
Vitamin C. Biosynthesis, recycling and degradation in mammals.
Asthma
Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma.
Aldose reductase inhibition for the treatment of asthma.
Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice.
Current Prospective of Aldose Reductase Inhibition in the Therapy of Allergic Airway Inflammation in Asthma.
Novel aldose reductase inhibitors: a patent survey (2006--present).
Astrocytoma
[Effect of AKR1A1 knock-down on H2;O2; and 4-hydroxynonenal-induced cytotoxicity in human 1321N1 astrocytoma cells].
Atherosclerosis
Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis.
Differential regulation of aldose reductase expression during macrophage polarization depends on hyperglycemia.
Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.
Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein e-/- mice.
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice.
Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis.
Blindness
Biochemical properties of purified human retinol dehydrogenase 12 (RDH12): catalytic efficiency toward retinoids and C9 aldehydes and effects of cellular retinol-binding protein type I (CRBPI) and cellular retinaldehyde-binding protein (CRALBP) on the oxidation and reduction of retinoids.
Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
[Pathophysiology of diabetic retinopathy and nephropathy]
Bone Diseases
[Effect of aldose reductase on the abnormality of calcium metabolism in diabetic patients]
Bone Diseases, Metabolic
Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Breast Neoplasms
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity.
Carcinogenesis
Adrenal tumorigenesis targeted by the corticotropin-regulated promoter of the aldo-keto reductase AKR1B7 gene in transgenic mice.
Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.
Diallyl sulfide protects against N-nitrosodiethylamine-induced liver tumorigenesis: role of aldose reductase.
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Gedunin abrogates aldose reductase, PI3K/Akt/mToR, and NF-?B signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis.
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex.
Carcinoma
Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes.
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases.
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Carcinoma, Ductal
Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity.
Carcinoma, Embryonal
Characterization of the functional gene encoding mouse class III alcohol dehydrogenase (glutathione-dependent formaldehyde dehydrogenase) and an unexpressed processed pseudogene with an intact open reading frame.
The role of alcohol dehydrogenase in retinoic acid homeostasis and fetal alcohol syndrome.
Carcinoma, Hepatocellular
Abnormal membrane phospholipid content in subcellular fractions from the Morris 7777 hepatoma.
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes.
Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Expression of differentiated functions in hepatoma cell hybrids. VI. Extinction and re-expression of liver alcohol dehydrogenase.
Further characterization of a rat hepatoma-derived aldose-reductase-like protein--organ distribution and modulation in vitro.
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Hypoglycemic activity of C-glycosyl flavonoid from Enicostemma hyssopifolium.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Induction of alcohol dehydrogenase activity and mRNA in hepatoma cells by dexamethasone.
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma.
Metabolic enzyme induction by HepG2 cells exposed to oxygenated and nonoxygenated polycyclic aromatic hydrocarbons.
Metabolism of gamma hydroxybutyrate in human hepatoma HepG2 cells by the aldo-keto reductase AKR1A1.
New data on kinetics of lipid peroxidation in experimental hepatomas and preneoplastic nodules.
New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma.
Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants.
Purification and catalytic properties of liver alcohol dehydrogenase isoenzymes in patients with hepatoma in Nigeria.
Quantitative Evaluation of Aldo-keto Reductase Expression in Hepatocellular Carcinoma (HCC) Cell Lines.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour.
Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
[Enzymes metabolizing xenobiotics in spontaneous tumors in mice]
[Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)]
Carcinoma, Intraductal, Noninfiltrating
Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity.
Carcinoma, Small Cell
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Carcinoma, Squamous Cell
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Cardiomegaly
Identification of a novel aldose reductase-like gene upregulated in the failing heart of cardiomyopathic hamster.
Cardiomyopathies
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition.
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats.
Cardiotoxicity
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.
Cardiovascular Diseases
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.
Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-?B and MAPK pathways.
Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
Carotid Artery Diseases
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
Cataract
A mouse model of galactose-induced cataracts.
A new approach against sugar cataract through aldose reductase inhibitors.
A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats.
A simple and stable galactosemic cataract model for rats.
A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes.
A thirty year journey in the polyol pathway.
Abnormal expression of aldose reductase mRNA in fiber cells of cataractous rat lens. Analysis by in situ hybridization.
Activation of aldose reductase by interaction with tubulin and involvement of this mechanism in diabetic cataract formation.
Additive effect of aldose reductase Z-4 microsatellite polymorphism and glycaemic control on cataract development in type 2 diabetes.
Age-dependent lens changes in galactose-fed dogs.
Aldehyde dehydrogenase, aldose reductase, and free radical scavengers in cataract.
Aldose reductase (EC 1.1.1.21) activity and reduced-glutathione content in lenses of diabetic sand rats (Psammomys obesus) fed with acarbose.
Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats.
Aldose reductase and its inhibition in the control of diabetic complications.
Aldose reductase and sorbitol dehydrogenase distribution in substructures of normal and diabetic rat lens.
Aldose reductase and the etiology of diabetic cataracts.
Aldose reductase expression as a risk factor for cataract.
Aldose reductase expression in human diabetic retina and retinal pigment epithelium.
Aldose reductase in diabetic cataracts.
Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture.
Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.
Aldose reductase inhibitors and cataract.
Aldose reductase inhibitors and galactose toxicity in neonatal and maternal rat lenses.
Aldose reductase inhibitors and prevention of galactose cataracts in rats.
Aldose reductase inhibitors from Litchi chinensis Sonn.
Aldose reductase inhibitory, anti-cataract and antioxidant potential of selected medicinal plants from the Marathwada region, India.
Aldose reductase mRNA is an epithelial cell-specific gene transcript in both normal and cataractous rat lens.
Aldose reductase the major protein associated with naphthalene dihydrodiol dehydrogenase activity in rat lens.
Aldose reductase, glucose and cataracts.
Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Aldose reductase-deficient mice develop nephrogenic diabetes insipidus.
Aldose reductase-mediated induction of epithelium-to-mesenchymal transition (EMT) in lens.
Analysis of sorbitol, galactitol, and myo-inositol in lens and sciatic nerve by high-performance liquid chromatography.
Anticataract activity of analogs of a sorbitol dehydrogenase inhibitor.
Antioxidant status in an in vitro model for hyperglycemic lens cataract formation: effect of aldose reductase inhibitor statil.
Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes.
Attenuation of aldose reductase gene suppresses high-glucose-induced apoptosis and oxidative stress in rat lens epithelial cells.
Bioactive fraction of Saraca indica prevents diabetes induced cataractogenesis: An aldose reductase inhibitory activity.
Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats.
Cataract prevention in diabetic Octodon degus with Pfizer's sorbinil.
Cataracts in experimentally diabetic mouse: morphological and apoptotic changes.
Changes of some biochemical parameters of the lens in galactose-treated weaned rats with and without vitamin E therapy.
Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat.
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
Corneal endothelial morphology in the rat. Effects of aging, diabetes, and topical aldose reductase inhibitor treatment.
Correlation between adult diabetic cataracts and red blood cell aldose reductase levels.
CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
Cytoprotective mechanism of action of curcumin against cataract.
Delayed progression of diabetic cataractogenesis and retinopathy by Litchi chinensis in STZ-induced diabetic rats.
Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens.
Determination of sorbitol and galactitol at the nanogram level in biological samples by high-performance liquid chromatography.
Developmental and physiological pattern of aldose reductase mRNA expression in lens and retina.
Diabetes can alter the signal transduction pathways in the lens of rats.
Diabetic and galactosaemic cataracts.
Diabetic cataracts and flavonoids.
Diabetic cataracts in animal models: prevention and reversibility with aldose reductase inhibitors.
Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
Dietary myo-inositol effect on sugar cataractogenesis.
Discovery of New Selective Human Aldose Reductase Inhibitors through Virtual Screening Multiple Binding Pocket Conformations.
Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation.
Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175.
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
Dynamic phosphorus-31 NMR study of sugar cataract and its prevention in rat lenses with aldose reductase inhibitors.
Effect of aldose reductase inhibitor on experimental diabetic cataract monitored by laser Raman spectroscopy.
Effect of aldose reductase inhibitors on lenticular dulcitol level in galactose fed rats.
Effect of aldose reductase inhibitors on naphthalene cataract formation in the rat.
Effect of an aldose reductase inhibitor, AL-1576, on the development of UV-B and X-ray cataract.
Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Effect of D-myo-inositol on platelet function and composition and on cataract development in streptozotocin-induced diabetic rats.
Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract.
Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
Effect of the isoflavone genistein against galactose-induced cataracts in rats.
Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
Effects of an aldose reductase inhibitor, 1-[(p-bromophenyl)-sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats.
Effects of galactose feeding on aldose reductase gene expression.
Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats.
Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats.
Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens.
Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose.
Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats.
Esculetin, a Coumarin Derivative, Inhibits Aldose Reductase Activity in vitro and Cataractogenesis in Galactose-Fed Rats.
Establishment of mouse as an animal model for study of diabetic cataracts: biochemical studies.
Establishment of the mouse as a model animal for the study of diabetic cataracts.
Evaluation of in vitro aldose reductase inhibitory potential of different fraction of Hybanthus enneaspermus Linn F. Muell.
Evolution of the aldose reductase-related gecko eye lens protein rhoB-crystallin: a sheep in wolf's clothing.
Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
Galactose-induced retinal microangiopathy in rats.
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells.
GP-1447, an inhibitor of aldose reductase, prevents the progression of diabetic cataract in rats.
Grape seed extract and Zinc containing nutritional food supplement delays onset and progression of Streptozocin-induced diabetic cataract in Wistar rats.
Identification of new urinary metabolites of byakangelicin, a component of Angelicae dahuricae Radix, in rats.
Idiopathic presenile cataract formation and galactosaemia.
Implications of aldose reductase in cataracts in human diabetes.
Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.
In utero and milk-mediated effect of aldose reductase inhibitor on galactose cataracts.
In Vitro and In Vivo Inhibitory Activities of Four Indian Medicinal Plant Extracts and their Major Components on Rat Aldose Reductase and Generation of Advanced Glycation Endproducts.
In vitro expression of rat lens aldose reductase in Escherichia coli.
Increased lenticular aldose reductase activity and high incidence of congenital cataract in the offspring of diabetic rats.
Inhibition in rat of development of in utero galactose-induced cataract by an aldose reductase inhibitor--a light microscopic study.
Inhibition of aldose reductase and xylose-induced lens opacity by puerariafuran from the roots of Pueraria lobata.
Inhibition of aldose reductase by Aegle marmelos and its protective role in diabetic cataract.
Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract.
Inhibition of aldose reductase from cataracted eye lenses by finger millet (Eleusine coracana) polyphenols.
Inhibition of aldose reductases from rat and bovine lenses by flavonoids.
Inhibition of glycation and aldose reductase activity using dietary flavonoids: A lens organ culture studies.
Inhibition of in utero galactose-induced cataract development by an aldose reductase inhibitor in rat--electron microscopic study.
Inhibition of lens aldose reductase by flavonoids--their possible role in the prevention of diabetic cataracts.
Inhibition of lens and cataract aldose reductase by protein-bound anti-rheumatic drugs: salicylate, indomethacin, oxyphenbutazone, sulindac.
Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
Inhibition of polyol formation in rat lens by verapamil.
Inhibitory effect of lycopene on cataract development in galactosemic rats.
Inhibitory effects of chlorogenic acid on aldose reductase activity in vitro and cataractogenesis in galactose-fed rats.
Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships.
Intrinsic inhibition of aldose reductase.
Investigation of synergistic mechanism and identification of interaction site of aldose reductase with the combination of gigantol and syringic acid for prevention of diabetic cataract.
Involvement of aldose reductase in naphthalene cataract.
Isolation of an aldose reductase inhibitor from the fruits of Vitex rotundifolia Part 2 in the series "Studies on the inhibitory effects of medicinal plant constituents on cataract formation".
Kinetic behaviour under defined assay conditions for bovine lens aldose reductase.
Lens aldose reductase in diabetic and galactosemic cataracts.
Lens aldose reductase inhibiting potential of some indigenous plants.
Levels of expression of hexokinase, aldose reductase and sorbitol dehydrogenase genes in lens of mouse and rat.
Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
Management of aldose reductase mRNA abundance in rat lens undergoing reversal of galactose induced cataracts. A model for gene response to changes in the environment.
Medical therapy in the prevention of cataract.
Melatonin Reduces Cataract Formation and Aldose Reductase Activity in Lenses of Streptozotocin-induced Diabetic Rat.
Metabolic cataracts in newly diagnosed diabetes.
Metabolic studies of galactosemic cataract.
Method for isolating tight-binding inhibitors of rat lens aldose reductase.
Methods for evaluation of medical therapy of senile and diabetic cataracts.
Modelling cortical cataractogenesis VII: Effects of vitamin E treatment on galactose-induced cataracts.
NADPH-oxidising activity in lens and erythrocytes in diabetic and nondiabetic patients with cataract.
Naphthalene-induced cataract in the rat. II. Contrasting effects of two aldose reductase inhibitors on glutathione and glutathione redox enzymes.
Natural therapies for ocular disorders, part two: cataracts and glaucoma.
Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes.
Nonosmotic diabetic cataracts.
Nutritional supplementation to prevent cataract formation.
Olive and ginkgo extracts as potential cataract therapy with differential inhibitory activity on aldose reductase.
Osmotic stress, not aldose reductase activity, directly induces growth factors and MAPK signaling changes during sugar cataract formation.
Overexpression of Na(+)-dependent myo-inositol transporter gene in mouse lens led to congenital cataract.
Overview of the current attempts toward the medical treatment of cataract.
Photographic and spectroscopic correlations of human cataracts.
Polyol accumulation in cultured human lens epithelial cells.
Polyol pathway-dependent osmotic and oxidative stresses in aldose reductase-mediated apoptosis in human lens epithelial cells: role of AOP2.
Potential use of aldose reductase inhibitors to prevent diabetic complications.
Prefeeding of aldose reductase inhibitor and galactose cataractogenesis.
Preventative Effects of Ginkgo biloba Extract (EGb761) on High Glucose-Cultured Opacity of Rat Lens.
Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat.
Prevention of naphthalene-1,2-dihydrodiol-induced lens protein modifications by structurally diverse aldose reductase inhibitors.
Preventive effect of chlorogenic acid on lens opacity and cytotoxicity in human lens epithelial cells.
Profile of messenger RNA decay in the Emory mouse lens in cataractogenesis and in aging.
Progression of sugar cataract in the dog.
Properties of an aldose reductase from pig lens. Comparative studies of an aldehyde reductase from pig lens.
Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
Pyruvate inhibits galactosemic changes in cultured cat lens epithelial cells.
Rabbit corneal and conjunctival permeability of the novel aldose reductase inhibitors: N-[[4-(benzoylamino)phenyl] sulphonyl]glycines and N-benzoyl-N-phenylglycines.
Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
Reduction of oxidative-nitrosative stress underlies anticataract effect of topically applied tocotrienol in streptozotocin-induced diabetic rats.
Relative abundance of aldose reductase mRNA in rat lens undergoing development of osmotic cataracts.
Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
Reversal of galactose cataract with Sorbinil in rats.
Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
Rho B-crystallin, an aldose reductase-like lens protein in the gecko Lepidodactylus lugubris.
Risk factors for cataract in Chinese patients with type 2 diabetes: evidence for the influence of the aldose reductase gene.
Role of aldose reductase in the development of diabetes-associated complications.
Role of dietary flavonoids in amelioration of sugar induced cataractogenesis.
Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract.
Scanning electron microscopy of X-ray-induced cataract in mice on normal and galactose diet.
Scopoletin Inhibits Rat Aldose Reductase Activity and Cataractogenesis in Galactose-Fed Rats.
Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking.
Sorbitol metabolism in inner medullary collecting duct cells of diabetic rats.
Structure-Activity Relationship Study Reveals Benzazepine Derivatives of Luteolin as New Aldose Reductase Inhibitors for Diabetic Cataract.
Studies on cataractogenesis in humans and in rats with alloxan-induced diabetes. II. Histochemical evaluation of lenticular enzymes.
Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
Sugar cataracts in vitro: implications of oxidative stress and aldose reductase I.
Sugar metabolism in the crystalline lens.
Synergism between phospholipase D2 and sorbitol accumulation in diabetic cataract formation through modulation of Na,K-ATPase activity and osmotic stress.
Synergism of sorbinil and normal diet on reversal of stage-II sugar cataract.
Synthesis and aldose reductase inhibitory activities of novel N-nitromethylsulfonanilide derivatives.
Synthesis and Biological Evaluation of Novel Gigantol Derivatives as Potential Agents in Prevention of Diabetic Cataract.
Syringic Acid Extracted from Herba dendrobii Prevents Diabetic Cataract Pathogenesis by Inhibiting Aldose Reductase Activity.
The aldose reductase inhibitor site.
The effect of aldose reductase and its inhibition on sugar cataract formation.
The effect of oxidation on sorbitol pathway kinetics.
The efficacy of aldose reductase inhibitor, antioxidant butylated hydroxytoluene and cysteine protease inhibitor E64 on hyperglycemia-induced metabolic changes in the organ-cultured bovine lens.
The efficacy of aldose reductase inhibitors on polyol accumulation in human lens and retinal pigment epithelium in tissue culture.
The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity.
The isolation and characterization of ?-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis.
The penetration of Sorbinil, an aldose reductase inhibitor, into lens, aqueous humour and erythrocytes of patients undergoing cataract extraction.
The possible mechanism of naphthalene cataract in rat and its prevention by an aldose reductase inhibitor (ALO1576).
The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis).
The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase.
Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies.
Thymol, a monoterpene, inhibits aldose reductase and high-glucose-induced cataract on isolated goat lens.
Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts.
Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1).
Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus.
Transient elevation of aldose reductase mRNA in lens of rats developing galactose cataracts.
Ultrastructural cytochemistry: effect of Sorbinil on arylsulfatases in cataractous lenses.
Up-regulation of P-glycoprotein expression by osmotic stress in rat sugar cataract.
Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
X-ray affinity and photoaffinity inhibitor of aldose reductase.
[Aldose reductase: physiological role, properties and prospects for regulating activity]
[Aldose-reductase inhibitors and cataract formation (author's transl)]
[Biochemical changes in lens, aqueous humor and vitreous body and effects of aldose reductase inhibitor (TAT) on rats with experimental diabetes]
[Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts]
[Magnetic resonance imaging study on rat sugar cataract]
[Morphological classification of the prevention by aldose reductase inhibitor of rat galactosemic cataract]
[Movement of regenerated lens epithelial cells in 50% galactose cataract and an aldose reductase inhibitor]
[Outlook for the future in the treatment of diabetic retinopathy]
[Prefeeding of aldose reductase inhibitor inhibits galactose cataract]
[Prevention and reversal of rat galactosemic cataract with aldose reductase inhibitor--immunohistochemical study]
[Prevention of galactose-induced cataractogenesis in rats by salvianolic acid A]
[Prevention of rat galactose cataract with topical aldose reductase inhibitor, E-1008]
[Preventional and therapeutic effects of aldose reductase inhibitor FR74366 on rat galactose cataract]
[Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanisms]
[Quantitative study of rat diabetic cataract, by the relaxation times of nuclear magnetic resonance]
[The inhibitory effect of aldose reductase inhibitor for proliferation in the lens epithelial cells of rat sugar cataract]
[The localization of aldose reductase mRNA in the rat lens]
[The role of lens epithelium in cataract formation in diabetic rats]
[What possibilities exist to modify cataract development on the basis of current biochemical knowledge? Where can drugs act?]
Cell Transformation, Neoplastic
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Central Nervous System Diseases
Defects in tongue papillae and taste sensation indicate a problem with neurotrophic support in various neurological diseases.
Choriocarcinoma
AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.
Colonic Neoplasms
Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
Aldose reductase inhibition prevents colon cancer growth by restoring PTEN through modulation of miR-21 and FOXO3a.
Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells.
Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.
Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells.
Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells.
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo.
Inhibition of aldose reductase prevents colon cancer metastasis.
Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis.
Colorectal Neoplasms
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldose Reductase Inhibitor Fidarestat as a Promising Drug Targeting Autophagy in Colorectal Carcinoma: a Pilot Study.
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice.
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Corneal Diseases
Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.
Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study.
Corneal Injuries
Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats.
Coronary Artery Disease
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
Dehydration
Acute changes in intracellular ions or pH and regulation of aldose reductase activity.
Osmolyte regulation by TonEBP/NFAT5 during anoxia-recovery and dehydration-rehydration stresses in the freeze-tolerant wood frog (Rana sylvatica).
Rehydration with Soft Drink-like Beverages Exacerbates Dehydration and Worsens Dehydration-associated Renal Injury.
Stopped-flow determination of the active form of acetaldehyde in the liver alcohol dehydrogenase catalyzed reaction.
Dementia
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Demyelinating Diseases
Cellular pathology of the nerve microenvironment in galactose intoxication.
Diabetes Complications
(2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase.
1-Benzopyran-4-one antioxidants as aldose reductase inhibitors.
1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.
1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor.
3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication.
3D-QSAR Studies on a Series of 5-Arylidine-2, 4-Thiazolidinediones as Aldose Reductase Inhibitors: A Self-Organizing Molecular Field Analysis Approach.
3D-QSAR studies on a series of 5-arylidine-2, 4-thiazolidinediones as aldose reductase inhibitors: a self-organizing molecular field analysis approach.
A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.
A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase.
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
A new approach against sugar cataract through aldose reductase inhibitors.
A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases.
A series of pyrido[2,3-b]pyrazin-3(4H)-one derivatives as aldose reductase inhibitors with antioxidant activity.
A thirty year journey in the polyol pathway.
Aberrant mRNA splicing causes sorbitol dehydrogenase deficiency in C57BL/LiA mice.
Active site modification of aldose reductase by nitric oxide donors.
Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA.
Aldo-keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy.
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Aldo-Keto Reductases 1B in Endocrinology and Metabolism.
Aldo-keto reductases as modulators of stress response.
Aldose and aldehyde reductase in animal tissues.
Aldose reductase and advanced glycation endproducts inhibitory effect of Phyllostachys nigra.
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.
Aldose reductase and its inhibition in the control of diabetic complications.
Aldose reductase and p-crystallin belong to the same protein superfamily as aldehyde reductase.
Aldose reductase and sorbitol dehydrogenase activities in diabetic brain: in vivo kinetic studies using 19F 3-FDG NMR in rats.
Aldose reductase deficiency protects sugar-induced lens opacification in rats.
Aldose reductase enzyme and its implication to major health problems of the 21(st) century.
Aldose reductase gene expression and osmotic dysregulation in cultured human retinal pigment epithelial cells.
Aldose reductase in diabetic complications of the eye.
Aldose reductase in diabetic microvascular complications.
Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
Aldose reductase in the etiology of diabetic complications. 3. Neuropathy.
Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
Aldose reductase in the etiology of diabetic complications: 4. Retinopathy.
Aldose reductase in the etiology of diabetic complications: I. Introduction.
Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
Aldose reductase inhibitors and diabetic complications.
Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics.
Aldose reductase inhibitors and the complications of diabetes mellitus.
Aldose reductase inhibitors and their potential for the treatment of diabetic complications.
Aldose reductase inhibitors for diabetic complications: Receptor induced atom-based 3D-QSAR analysis, synthesis and biological evaluation.
Aldose reductase inhibitors from Viola hondoensis W. Becker et H Boss.
Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism.
Aldose Reductase Inhibitors of Plant Origin.
Aldose reductase inhibitors.
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Aldose reductase inhibitors: an update.
Aldose reductase inhibitors: therapeutic implications for diabetic complications.
Aldose reductase inhibitory activity and antioxidant capacity of pomegranate extracts.
Aldose reductase inhibitory activity of compounds from Zea mays L.
Aldose reductase inhibitory compounds from Glycyrrhiza uralensis.
Aldose Reductase Inhibitory Compounds from Xanthium strumarium.
Aldose reductase inhibitory effect by tectorigenin derivatives from Viola hondoensis.
Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages.
Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis.
Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Aldose reductase, oxidative stress and diabetic cardiovascular complications.
ALDOSE REDUCTASE: New Insights for an Old Enzyme.
Alkaloids as aldose reductase inhibitors, with special reference to berberine.
All in the family: aldose reductase and closely related aldo-keto reductases.
An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.
An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.
Anti-hyperglycemic effect of Potentilla discolor decoction on obese-diabetic (Ob-db) mice and its chemical composition.
Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice.
Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.
Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients.
Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies.
Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies.
Bioassay-guided isolation of aldose reductase inhibitors from Artemisia dracunculus.
Bioavailability, multiple-dose pharmacokinetics, and biotransformation of the aldose reductase inhibitor zopolrestat in dogs.
Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling.
Carboxymethylated tetrahydropyridoindoles as aldose reductase inhibitors: in vitro selectivity study in intact rat erythrocytes in relation to glycolytic pathway.
Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.
Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Characterization of genomic regions directing the cell-specific expression of the mouse aldose reductase gene.
Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
Clinical significance of erythrocyte sorbitol-blood glucose ratios in type II diabetes mellitus.
Clinical trials with aldose reductase inhibitors.
Cloning and expression of human aldose reductase.
Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Comparisons of genomic structures and chromosomal locations of the mouse aldose reductase and aldose reductase-like genes.
CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily.
Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.
Deficiency of ascorbic acid in experimental diabetes. Relationship with collagen and polyol pathway abnormalities.
Design and synthesis of chiral 2H-chromene-N-imidazolo-amino acid conjugates as aldose reductase inhibitors.
Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.
Design and synthesis of pyridazinone-substituted benzenesulphonylurea derivatives as anti-hyperglycaemic agents and inhibitors of aldose reductase - an enzyme embroiled in diabetic complications.
Determination of sorbitol and galactitol at the nanogram level in biological samples by high-performance liquid chromatography.
Development and validation of a rapid high-performance liquid chromatography-tandem mass spectrometry method for the determination of WJ-38, a novel aldose reductase inhibitor, in rat plasma and its application to a pharmacokinetic study.
Development of novel pyrazolone derivatives as inhibitors of aldose reductase: An eco-friendly one-pot synthesis, experimental screening and in silico analysis.
Development of potent aldose reductase inhibitors having a hydantoin structure.
Developmental and physiological regulation of aldose reductase mRNA expression in renal medulla.
Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.
Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Discovery of new inhibitors of aldose reductase from molecular docking and database screening.
Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis.
Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Disruption of aldose reductase gene (Akr1b1) causes defect in urinary concentrating ability and divalent cation homeostasis.
Does aldose reductase have a role in the development of the ocular complications of diabetes?
Does sorbinil bind to the substrate binding site of aldose reductase?
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
DW1029M, a novel botanical drug candidate, inhibits advanced glycation end product formation, rat lens aldose reductase activity, and TGF?1 signaling.
Edible vegetables as a source of aldose reductase differential inhibitors.
Effect of a novel mutation in 5'-regulatory region of aldose reductase gene on its expression.
Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.
Effects of a new aldose reductase inhibitor on diabetic complications in rats.
Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats.
Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.
Effects of galactose feeding on aldose reductase gene expression.
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Efficacy of glucose, ouabain and an aldose reductase inhibitor on 2-[3H] myo-inositol uptake by human, rat and rabbit erythrocytes.
Enzyme immunoassay for erythrocyte aldose reductase.
Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
Erythrocyte aldose reductase correlates with erectile dysfunction in diabetic patients.
Evaluation of aldose reductase inhibition and docking studies of 6'-nitro and 6',6''-dinitrorosmarinic acids.
Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study.
Evaluation of in vitro aldose reductase inhibitory potential of alkaloidal fractions of Piper nigrum, Murraya koenigii, Argemone mexicana, and Nelumbo nucifera.
Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262.
Extraction and identification of three major aldose reductase inhibitors from Artemisia montana.
Fibrates inhibit aldose reductase activity in the forward and reverse reactions.
Functional genomic studies of aldo-keto reductases.
Genetic analysis of aldose reductase in diabetic complications.
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells.
High-resolution neutron protein crystallography with radically small crystal volumes: application of perdeuteration to human aldose reductase.
Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Highly selective aldose reductase inhibitors. II. Optimization of the aryl part of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Hormonal regulation of aldose reductase in rat ovary during the estrous cycle.
Human liver 6-pyruvoyl tetrahydropterin reductase is biochemically and immunologically indistinguishable from aldose reductase.
Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Identification of an aldose reductase inhibitor site by affinity labeling.
Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
In Vitro and In Vivo Inhibitory Activities of Four Indian Medicinal Plant Extracts and their Major Components on Rat Aldose Reductase and Generation of Advanced Glycation Endproducts.
In-vitro assessment of a hypersensitivity syndrome associated with sorbinil.
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Increased white cell aldose reductase mRNA levels in diabetic patients.
Inhibition behaviours of some phenolic acids on rat kidney aldose reductase enzyme: an in vitro study.
Inhibition of aldose reductase by flavonoids: possible attenuation of diabetic complications.
Inhibition of aldose reductase by phenylethanoid glycoside isolated from the seeds of Paulownia coreana.
Inhibition of aldose reductase from human retina.
Inhibition of phosphatidylinositol synthase by glucose in human retinal pigment epithelial cells.
Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts.
Inhibitory activities of selected Kampo formulations on human aldose reductase.
Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase.
Inhibitory activity of Aralia continentalis roots on protein tyrosine phosphatase 1B and rat lens aldose reductase.
Inhibitory constituents of aldose reductase in the fruiting body of Phellinus linteus.
Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity.
Inhibitory effect of total lignan from Fructus Arctii on aldose reductase.
Inhibitory effect of ursolic acid derivatives on recombinant human aldose reductase.
Inhibitory effects of 2'-hydroxychalcones on rat lens aldose reductase and rat platelet aggregation.
Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
Inhibitory effects of Nelumbo nucifera leaves on rat lens aldose reductase, advanced glycation endproducts formation, and oxidative stress.
Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships.
Inhibitory effects of Zingiber officinale Roscoe derived components on aldose reductase activity in vitro and in vivo.
Intrinsic inhibition of aldose reductase.
Inventing and understanding catalytic, enantioselective reactions.
Is sorbitol dehydrogenase gene expression affected by streptozotocin-diabetes in the rat?
Isoflavonoids from the rhizomes of Belamcanda chinensis and their effects on aldose reductase and sorbitol accumulation in streptozotocin induced diabetic rat tissues.
Isolation and characterization of cDNA clones encoding aldose reductase.
Kinetic and molecular docking studies of loganin and 7-O-galloyl-D-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase.
Kinetic and structural characterization of the glutathione-binding site of aldose reductase.
Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase.
Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
Localization of aldose reductase in the human eye.
Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
Long-term induction of an aldose reductase protein by basic fibroblast growth factor in rat astrocytes in vitro.
Mechanism of capsaicin inhibition of aldose reductase activity.
Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications.
Method for isolating tight-binding inhibitors of rat lens aldose reductase.
Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase.
Methylglyoxal, glyoxalases and the development of diabetic complications.
Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes.
Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
Modelling of aldose reductase inhibitory activity of pyrrol-1-yl-acetic acid derivatives by means of multivariate statistics.
Modelling the catalytic reaction in human aldose reductase.
Modulation of aldose reductase activity by aldose hemiacetals.
Molecular cloning of testicular 20 alpha-hydroxysteroid dehydrogenase: identity with aldose reductase.
Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins.
New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition.
Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes.
Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells.
Nitric oxide up-regulates aldose reductase expression in rat vascular smooth muscle cells: a potential role for aldose reductase in vascular remodeling.
No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
Noninvasive evaluation of effects of an aldose reductase inhibitor in rat brain by 19F FDG NMR spectroscopy.
Novel aldose reductase inhibitors: a patent survey (2006--present).
Novel sites of aldose reductase immunolocalization in normal and streptozotocin-diabetic rats.
Nutritional Overview on the Management of Type 2 Diabetes and the Prevention of its Complications.
Oral baicalin and liquid extract of licorice reduce sorbitol levels in red blood cell of diabetic rats.
Osmolarity and glucose differentially regulate aldose reductase activity in cultured mouse podocytes.
Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-?1 expression in mesangial cells under diabetic conditions.
Oxidized aldose reductase: in vivo factor not in vitro artifact.
Phospho-Site-Specific Antibody Microarray to Study the State of Protein Phosphorylation in the Retina.
Plants used in the management of diabetic complications.
Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors.
Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain.
Potential use of aldose reductase inhibitors to prevent diabetic complications.
Presence of a closely related subgroup in the aldo-ketoreductase family of the mouse.
Presence of aldose reductase inhibitors in tea leaves.
Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry.
Production of crystals of human aldose reductase with very high resolution diffraction.
Profile of aldose reductase inhibition, anti-cataract and free radical scavenging activity of selected medicinal plants: an attempt to standardize the botanicals for amelioration of diabetes complications.
Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.
Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
Protein structure-based de novo design and synthesis of aldose reductase inhibitors.
Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Immunoassay of human aldose reductase.
Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy.
Rat kidney aldose reductase and aldehyde reductase and polyol production in rat kidney.
Rat lens aldose reductase: rapid purification and comparison with human placental aldose reductase.
Recent clinical experience with aldose reductase inhibitors.
Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications.
Reductive detoxification of acrolein as a potential role for aldehyde reductase (AKR1A) in mammals.
Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat.
Regulation of the human taurine transporter by oxidative stress in retinal pigment epithelial cells stably transformed to overexpress aldose reductase.
Residues affecting the catalysis and inhibition of rat lens aldose reductase.
Restriction fragment length polymorphisms of the human aldose reductase gene: a preliminary report.
Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy.
Role of polyol pathway in nonenzymatic glycation.
Screening of Korean forest plants for rat lens aldose reductase inhibition.
Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
Sorbitol metabolism in inner medullary collecting duct cells of diabetic rats.
Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications.
Spiro hydantoin aldose reductase inhibitors.
Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.
Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.
Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
Structural bases for the inhibition of aldose reductase by phenolic compounds.
Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
Substituted derivatives of indole acetic acid as aldose reductase inhibitors with antioxidant activity: structure-activity relationship.
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate.
Sulfonyl group-containing compounds in the design of potential drugs for the treatment of diabetes and its complications.
Symposium: Aldose reductase and the complications of diabetes mellitus: reviews of preclinical studies in eyes, nerves, and kidneys. London, September 1984. Proceedings.
Synthesis and activity of a new series of (Z)-3-phenyl-2-benzoylpropenoic acid derivatives as aldose reductase inhibitors.
Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives.
Synthesis and structure-activity relationship studies of quinoxaline derivatives as aldose reductase inhibitors.
Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors.
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
The activity of aldose reductase is elevated in diabetic mouse heart.
The aldose reductase inhibitor site.
The aldose reductase inhibitory capacity of Sorbus domestica fruit extracts depends on their phenolic content and may be useful for the control of diabetic complications.
The combined extract of purple waxy corn and ginger prevents cataractogenesis and retinopathy in streptozotocin-diabetic rats.
The crystal structure of the aldose reductase.NADPH binary complex.
The effect of hypertonicity on aldose reductase, alpha B-crystallin, and organic osmolytes in the retinal pigment epithelium.
The effect of non-enzymatic glycation on recombinant human aldose reductase.
The Effect of Urinary pH and Flow Rate on the Renal Elimination of Zopolrestat and Zopolrestat Glucuronide in Humans.
The effects of streptozotocin-induced diabetes and aldose reductase inhibition with sorbinil, on left and right atrial function in the rat.
The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
The Human Aldose Reductase AKR1B1 Qualifies as the Primary Prostaglandin F Synthase in the Endometrium.
The identification of aldose reductase in the pathogenesis of diabetic complications: the background.
The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity.
The inhibitory effect of benzodiazepine derivatives on the bovine lens aldose reductase enzyme.
The involvement of aldose reductase in diabetic complications.
The role of aldose reductase in the development of diabetic complications.
The role of aldose reductase inhibitors in diabetic complications: recent trends.
Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies.
Three-dimensional quantitative structure-activity relationships and docking studies of some structurally diverse flavonoids and design of new aldose reductase inhibitors.
Thymol, a monoterpene, inhibits aldose reductase and high-glucose-induced cataract on isolated goat lens.
Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats.
Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor-regulated protein in the adrenal gland.
Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase.
Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
Zopolrestat as a human glyoxalase?i inhibitor and its structural basis.
[Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications]
[Ciliary body changes associate with aldose reductase in galactosemic rats (2)]
[Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications]
[Effects of silybin on red blood cell sorbitol and nerve conduction velocity in diabetic patients]
[Effects of transgenic expression of human aldose reductase on diabetic complications]
[Effects of transgenic human aldose reductase and sorbitol dehydrogenase deficiency on diabetes complications]
[Progress in research of aldose reductase inhibitors in traditional medicinal herbs]
[Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors]
[Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors]
Diabetes Insipidus
Genetic restoration of aldose reductase to the collecting tubules restores maturation of the urine concentrating mechanism.
Diabetes Mellitus
(AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
(CA)(n) dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene is not associated with microangiopathy in Caucasians with long-term diabetes mellitus 1.
31P NMR studies of the diabetic lens.
Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Aldose reductase (AC)(n) microsatellite polymorphism and diabetic microvascular complications in Caucasian Type 1 diabetes mellitus.
Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats.
Aldose reductase and IGF-I gene expression in aortic and arteriolar smooth muscle during hypo- and hyperinsulinemic diabetes.
Aldose reductase and sorbitol dehydrogenase activities in diabetic brain: in vivo kinetic studies using 19F 3-FDG NMR in rats.
Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus.
Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus.
Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Aldose reductase inhibitors and diabetic complications.
Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics.
Aldose reductase inhibitors and the complications of diabetes mellitus.
Aldose reductase inhibitors: an update.
Aldose reductase messenger RNA in the lens epithelium in vivo: effects of diabetes mellitus and galactosaemia.
Aldose reductase-deficient mice develop nephrogenic diabetes insipidus.
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus.
Anti-hyperglycemic effect of Potentilla discolor decoction on obese-diabetic (Ob-db) mice and its chemical composition.
Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus.
Association of aldose reductase gene (AKR1B1) polymorphism with diabetic retinopathy.
Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus.
Association of c(-106)t polymorphism in aldose reductase gene with diabetic retinopathy in chinese patients with type 2 diabetes mellitus.
Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies.
C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus.
Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.
Clinical significance of erythrocyte sorbitol-blood glucose ratios in type II diabetes mellitus.
Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.
Design, Synthesis and Evaluation of Rhodanine Derivatives as Aldose Reductase Inhibitors.
Determinants of retinopathy progression in type 1 diabetes mellitus.
Developmental and physiological regulation of aldose reductase mRNA expression in renal medulla.
Diabetic neuropathy in elderly patients. What can be done?
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
Effect of a novel mutation in 5'-regulatory region of aldose reductase gene on its expression.
Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy.
Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model.
Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes.
Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.
Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship.
Impaired myelinated fiber regeneration following freeze-injury in rats with streptozotocin-induced diabetes: involvement of the polyol pathway.
Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Minalrestat and leukocyte migration in diabetes mellitus.
Morphological and functional changes in the diabetic peripheral nerve: using diagnostic ultrasound and neurosensory testing to select candidates for nerve decompression.
Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.
Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus.
Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus.
Preventing and treating actions of compound lian zhu capsule on micrangium lesions in diabetic rats.
Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.
Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
Renal gene expression in embryonic and newborn diabetic mice.
Retinal dystrophy: development retarded by galactose feeding in spontaneously hypertensive rats.
Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats.
Risk factors for progression of distal symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research Group.
Sorbinil does not prevent hyperfiltration, elevated ultrafiltration pressure and albuminuria in streptozotocin-diabetic rats.
Spiro hydantoin aldose reductase inhibitors.
Spirohydantoin inhibitors of aldose reductase inhibit iron- and copper-catalysed ascorbate oxidation in vitro.
Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
Substance P levels in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats with long-term diabetes mellitus. Effects of aldose reductase inhibition.
Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene.
Symposium: Aldose reductase and the complications of diabetes mellitus: reviews of preclinical studies in eyes, nerves, and kidneys. London, September 1984. Proceedings.
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
The crystal structure of the aldose reductase.NADPH binary complex.
The effect of aldose reductase inhibition with ponalrestat on the width of the capillary basement membrane in diabetes mellitus.
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation.
The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus.
The structures of Alcaligenes faecalis D-3-hydroxybutyrate dehydrogenase before and after NAD+ and acetate binding suggest a dynamical reaction mechanism as a member of the SDR family.
Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus.
[Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy]
[Polymorphism of aldose reductase gene and susceptibility to retinopathy and nephropathy in Caucasians with type 1 diabetes]
[The role of methylglyoxal in the development of diabetic complications]
[Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors]
[Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors]
[Two forms of aldose reductase in erythrocytes from patients with insulin-dependent diabetes mellitus]
Diabetes Mellitus, Experimental
Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
Amelioration of glomerular hyperfiltration in acute experimental diabetes mellitus by dietary myo-inositol supplementation and aldose reductase inhibition.
Control of sorbitol metabolism in renal inner medulla of diabetic rats: regulation by substrate, cosubstrate and products of the aldose reductase reaction.
Effect of streptozotocin diabetes on motor and inhibitory transmission in rat anococcygeus.
Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus.
Studies of sorbinil on axonal transport in streptozotocin-diabetic rats.
The effect of aldose reductase inhibition and dietary protein restriction on renal function in experimental diabetes mellitus.
The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
[Status of the monooxygenase enzyme system in rat and rabbit organs in sugar diabetes and upon insulin administration]
Diabetes Mellitus, Type 1
A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes.
Aldose reductase (AC)(n) microsatellite polymorphism and diabetic microvascular complications in Caucasian Type 1 diabetes mellitus.
Aldose reductase gene expression is increased in diabetic nephropathy.
Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus.
Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus.
Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
Determinants of retinopathy progression in type 1 diabetes mellitus.
Diabetic nephropathy is associated with the 5'-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes.
Diabetic neuropathy.
Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
Effect of an aldose reductase inhibiting agent on limited joint mobility in IDDM.
Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy.
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Neutrophil aldose reductase activity and its association with established diabetic microvascular complications.
No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus.
Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy.
Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition.
Risk factors for progression of distal symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research Group.
Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group.
Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
[Polymorphism of aldose reductase gene and susceptibility to retinopathy and nephropathy in Caucasians with type 1 diabetes]
[Polymorphism of the dinucleotide repeat inside the aldose reductase gene in normal states and in patients with insulin-dependent diabetes mellitus with vascular complications]
[The pathogenetic characteristics and the possible ways for the pharmacological correction of insulin-dependent diabetes mellitus]
[Two forms of aldose reductase in erythrocytes from patients with insulin-dependent diabetes mellitus]
Diabetes Mellitus, Type 2
(AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Additive effect of aldose reductase Z-4 microsatellite polymorphism and glycaemic control on cataract development in type 2 diabetes.
Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians.
Aldose reductase C-106T gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes.
Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes.
Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes.
Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus.
Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
Association of aldose reductase gene (AKR1B1) polymorphism with diabetic retinopathy.
Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus.
Association of c(-106)t polymorphism in aldose reductase gene with diabetic retinopathy in chinese patients with type 2 diabetes mellitus.
Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients.
Association of retinopathy with a microsatellite at 5' end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes.
C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control.
C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus.
Chemometrics Optimized Extraction Procedures, Phytosynergistic Blending and in vitro Screening of Natural Enzyme Inhibitors Amongst Leaves of Tulsi, Banyan and Jamun.
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
Diabetic nephropathy is associated with the 5'-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes.
Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes.
Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT.
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Effect of a novel mutation in 5'-regulatory region of aldose reductase gene on its expression.
Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus.
Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine.
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients.
Epithelial cell density in cataractous lenses of patients with diabetes: association with erythrocyte aldose reductase.
Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship.
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy.
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Neutrophil aldose reductase activity and its association with established diabetic microvascular complications.
Oxidative stress and male IGF-1, gonadotropin and related hormones in diabetic patients.
Pathological mechanisms involved in diabetic neuropathy: can we slow the process?
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes: response to Wang et al.
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.
Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus.
Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients.
Risk factors for cataract in Chinese patients with type 2 diabetes: evidence for the influence of the aldose reductase gene.
The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes.
The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.
The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy.
The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.
Virtual screening of plant derived compounds for aldose reductase inhibition using molecular docking.
Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro.
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]
Diabetic Angiopathies
Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals.
Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients.
Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese Type 2 diabetic (T2DM) patients.
Diabetes-induced increases in vascular permeability and changes in granulation tissue levels of sorbitol, myo-inositol, chiro-inositol, and scyllo-inositol are prevented by sorbinil.
Effect of an aldose reductase inhibitor on type IV collagen production by human endothelial cells cultured in high glucose.
Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
Microangiopathy in diabetes mellitus: I. Causes, prevention and treatment.
Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
The effect of aldose reductase inhibition by JMC-2004 on hyperglycemia-induced endothelial dysfunction.
[Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor]
Diabetic Nephropathies
(AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
Aldose reductase and the role of the polyol pathway in diabetic nephropathy.
Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy.
Aldose reductase gene expression is increased in diabetic nephropathy.
Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus.
Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus.
Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients.
Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.
Aldose reductase inhibition, glomerular metabolism, and diabetic nephropathy.
Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.
Aldose reductase inhibitors and diabetic kidney disease.
Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgf?1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice.
Aldose reductase, glomerular metabolism, and diabetic nephropathy.
Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus.
Association between (AC)n dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene and diabetic nephropathy: a meta-analysis.
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients.
Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients.
C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control.
C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus.
Cyclocarya paliurus extract alleviates diabetic nephropathy by inhibiting oxidative stress and aldose reductase.
Diabetic nephropathy is associated with the 5'-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes.
Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes.
Diabetic nephropathy--prevention and treatment.
Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
DW1029M, a novel botanical drug candidate, inhibits advanced glycation end product formation, rat lens aldose reductase activity, and TGF?1 signaling.
Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathy.
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.
Gene expression and identification of gene therapy targets in diabetic nephropathy.
Genetic deficiency of aldose reductase counteracts the development of diabetic nephropathy in C57BL/6 mice.
Glomerular changes in diabetes mellitus.
Glucose transporters of the glomerulus and the implications for diabetic nephropathy.
High glucose induction of DNA-binding activity of the transcription factor NFkappaB in patients with diabetic nephropathy.
Identification of a renal-specific oxido-reductase in newborn diabetic mice.
Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
Is rs759853 polymorphism in promoter of aldose reductase gene a risk factor for diabetic nephropathy? A meta-analysis.
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Novel insights in the treatment of diabetic nephropathy.
Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes.
Polyol pathway and diabetic nephropathy revisited: Early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase.
Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.
Relevance of aldo-keto reductase family members to the pathobiology of diabetic nephropathy and renal development.
Role of aldose reductase in the high glucose induced expression of fibronectin in human mesangial cells.
Short Report : TreatmentLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes.
The 5'-end polymorphism of the aldose reductase gene is not associated with diabetic nephropathy in Caucasian type I diabetic patients.
The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
The effects of aldose reductase inhibitors in diabetic nephropathy.
The localisation of sorbitol pathway activity in the rat renal cortex and its relationship to the pathogenesis of the renal complications of diabetes mellitus.
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus.
Variants in the gene encoding aldose reductase (AKR1B1) and diabetic nephropathy in American Indians.
Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy.
[Effect of liuwei dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients]
[Effects of Shendan Jianyi Capsule on aldose reductase activity of kidney in diabetic rats]
[Progress in research of aldose reductase inhibitors in traditional medicinal herbs]
[The role of cellular glucose transporters in pathogenesis of diabetic nephropathy]
[The role of genetic studies in finding the etiopathogenesis of diabetes mellitus]
Diabetic Neuropathies
A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.
A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: relationship to myo-inositol metabolism and nerve conduction slowing.
Advanced Diabetic Neuropathy: A Point of no Return?
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Aldose reductase inhibition for diabetic neuropathy.
Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
Aldose reductase inhibitors in clinical practice. Preliminary studies on diabetic neuropathy and retinopathy.
Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy.
Aldose reductase structures: implications for mechanism and inhibition.
Aldose reductase, still a compelling target for diabetic neuropathy.
Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat.
An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
Anti-platelet action of GU-7, a 3-arylcoumarin derivative, purified from glycyrrhizae radix.
Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model.
Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy in rats.
Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.
Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
Decreased endoneurial fluid electrolytes in normal rat sciatic nerve after aldose reductase inhibition.
Diabetic neuropathy in db/db mice develops independently of changes in ATPase and aldose reductase. A biochemical and immunohistochemical study.
Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT.
Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment.
Diabetic neuropathy.
Diabetic peripheral neuropathy.
Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years.
Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy.
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.
Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat.
Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study.
Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
Emerging drugs for diabetic neuropathy.
Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.
Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells.
Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation.
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective.
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines.
Fidarestat improves cardiomyocyte contractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism.
Fidarestat. Sanwa Kagaku/NC Curex/Sankyo.
Further clinical studies with an aldose reductase inhibitor in diabetic neuropathy.
Galactose neuropathy. Structural changes evaluated by nuclear magnetic resonance spectroscopy.
Galactosemic neuropathy in transgenic mice for human aldose reductase.
I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
LC-MS/MS method for the quantification of aldose reductase inhibitor - epalrestat and application to pharmacokinetic study.
Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
Lower limb problems in diabetic patients. What are the causes? What are the remedies?
Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study.
Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy.
One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
Pathogenesis of diabetic neuropathy--do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?
Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
Pharmacologic intervention in axonal excitability: in vivo assessment of nodal persistent sodium currents in human neuropathies.
Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.
Polyol pathway and diabetic neuropathy: selective preventive effects of an aldose reductase inhibitor in experimental diabetic neuropathy.
Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats.
Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
Pyridine nucleotide redox abnormalities in diabetes.
Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy.
Recent advances in the management of diabetic distal symmetrical polyneuropathy.
Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
Short Report : TreatmentLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve.
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Studies of aldose reductase using neuronal cell culture and ligated rat sciatic nerve.
Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats.
Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene.
The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents.
The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy.
The involvement of aldose reductase in alterations to neurotrophin receptors and neuronal cytoskeletal protein mRNA levels in the dorsal root ganglion of streptozotocin-induced diabetic rats.
The pathogenesis and prevention of diabetic neuropathy and nephropathy.
The pathology of diabetic neuropathy and the effects of aldose reductase inhibitors.
The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Tolrestat improves nerve regeneration after crush injury in streptozocin-induced diabetic rats.
Tolrestat pharmacokinetics in rat peripheral nerve.
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress.
Transition metals and polyol pathway in the development of diabetic neuropathy in rats.
Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.
Treatment of diabetic neuropathy with inhibitors of the aldose reductase enzyme.
Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity.
[Aldose reductase inhibitors in diabetic neuropathy]
[Correction of diabetic neuropathies using aldose reductase inhibitors and pikamilon]
[Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy]
[Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)]
[Diabetic neuropathy].
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]
[Inhibition effect of epalrestat on rat lens osmotic expansion]
[Role of the polyol pathway in the occurrence of degenerative complications of diabetes]
[Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?]
Diabetic Retinopathy
A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes.
A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group.
A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
A systematic meta-analysis of genetic association studies for diabetic retinopathy.
Aldo-keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy.
Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians.
Aldose Reductase / Polyol Inhibitors For Diabetic Retinopathy.
Aldose reductase activity in retinal and cerebral microvessels and cultured vascular cells.
Aldose reductase and diabetic retinopathy.
Aldose reductase C-106T gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes.
Aldose reductase gene polymorphisms and diabetic retinopathy susceptibility.
Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture.
Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
Aldose Reductase Inhibition Prevents Endotoxin-Induced Inflammatory Responses in Retinal Microglia.
Aldose reductase, diabetes, and thickening of the retinal inner limiting membrane.
Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
An aldose reductase intragenic polymorphism associated with diabetic retinopathy.
Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects.
Association of aldose reductase gene (AKR1B1) polymorphism with diabetic retinopathy.
Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus.
Association of c(-106)t polymorphism in aldose reductase gene with diabetic retinopathy in chinese patients with type 2 diabetes mellitus.
Association of retinopathy with a microsatellite at 5' end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes.
Association of the Aldose Reductase-106TT Genotype with Increased Risk for Diabetic Retinopathy in the Chinese Han Population: An Updated Meta-Analysis.
Bioinformatics analysis of diabetic retinopathy using functional protein sequences.
C(-106)T polymorphism of the aldose reductase gene and the progression rate of diabetic retinopathy.
Calcium dobesilate in the treatment of diabetic retinopathy.
Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
Current and future pharmacological intervention for diabetic retinopathy.
Current progress in clinical trials of aldose reductase inhibitors in Japan.
Deletion of aldose reductase from mice inhibits diabetes-induced retinal capillary degeneration and superoxide generation.
Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor.
Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes.
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.
Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175.
DW1029M, a novel botanical drug candidate, inhibits advanced glycation end product formation, rat lens aldose reductase activity, and TGF?1 signaling.
Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats.
Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial.
Efficacy of treatment after measurable diabeticlike retinopathy in galactose-fed rats.
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy.
Functional genomic studies of aldo-keto reductases.
Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats.
High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process.
Keeping an eye on vision: new tools to preserve sight and quality of life. A roundtable discussion, Part 2.
Length rather than a specific allele of dinucleotide repeat in the 5' upstream region of the aldose reductase gene is associated with diabetic retinopathy.
NIH conference. Aldose reductase and complications of diabetes.
Novel transgenic mouse models develop retinal changes associated with early diabetic retinopathy similar to those observed in rats with diabetes mellitus.
On the pathogenesis of diabetic retinopathy.
On the pathogenesis of diabetic retinopathy. A 1990 update.
Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus.
Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus.
Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors.
Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors.
Screening for and managing diabetic retinopathy: current approaches.
Short Report : TreatmentLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model.
Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy.
Targeting the retinal microcirculation to treat diabetic sight problems.
The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes.
The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents.
The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy.
The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.
The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
The effects of elevated glucose on Na+/K(+)-ATPase of cultured bovine retinal pigment epithelial cells measured by a new nonradioactive rubidium uptake assay.
The inhibitory effect of Isoflavones isolated from Caesalpinia pulcherrima on aldose reductase in STZ induced diabetic rats.
The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy.
The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient.
The Relationship between Aldose reductase C-106T polymorphism and Diabetic retinopathy?An Updated Meta-analysis.
Tonicity-responsive enhancer binding protein regulates the expression of aldose reductase and protein kinase C ? in a mouse model of diabetic retinopathy.
Z-2 aldose reductase allele and diabetic retinopathy in India.
[Association study between diabetic retinopathy and aldose reductase gene polymorphism in Tunisians]
[Prevention of pericyte ghost formation in retinal capillaries by aldose reductase inhibitor in galactose-fed dogs with diabetic retinopathy]
[Role of aldose reductase in the progression of diabetic retinopathies]
[The biochemical mechanism in vitro of pericyte drop-out in diabetic retinopathy]
[What is the etiology of diabetic retinopathy?]
Down Syndrome
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Drug Hypersensitivity
Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase.
Dyslipidemias
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Therapeutic interventions for nephropathy in type I diabetes mellitus.
Endometrial Neoplasms
Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening.
Epilepsy
Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening.
Erectile Dysfunction
Erythrocyte aldose reductase correlates with erectile dysfunction in diabetic patients.
[Is it possible to prevent andrological complications in the diabetic patient?]
Eye Diseases
Aldose reductase expression as a risk factor for cataract.
Exclusion of aldose reductase as a mediator of ERG deficits in a mouse model of diabetic eye disease.
Fatty Liver
Ethanol metabolism, cirrhosis and alcoholism.
Fibrosarcoma
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Galactosemias
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Analysis of sorbitol, galactitol, and myo-inositol in lens and sciatic nerve by high-performance liquid chromatography.
Changes of some biochemical parameters of the lens in galactose-treated weaned rats with and without vitamin E therapy.
Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor.
Diabetic cataracts and flavonoids.
Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats.
Effect of galactose diet removal on the progression of retinal vessel changes in galactose-fed dogs.
Effect of the isoflavone genistein against galactose-induced cataracts in rats.
Fluorometric studies on the blood-retinal barrier in experimental animals.
Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor.
Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallins of rats with chronic galactosemia: prevention by the aldose reductase inhibitor sorbinil.
Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
Reversal of galactose cataract with Sorbinil in rats.
Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase.
Synthesis and evaluation of novel aldose reductase inhibitors: Effects on lens protein kinase Cgamma.
The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
Time-dependent aspects of osmolyte changes in rat kidney, urine, blood and lens with sorbinil and galactose feeding.
Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Relationship to pentosidine cross-links.
Gastrointestinal Neoplasms
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
Gastroparesis
Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Glaucoma
Keeping an eye on vision: new tools to preserve sight and quality of life. A roundtable discussion, Part 2.
Glioblastoma
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Glomerulonephritis
[Effect of aldose reductase expression by transforming growth factor-beta1 on rat mesangial cell]
Glomerulonephritis, Membranous
Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.
Glycosuria
Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
Heart Arrest
Proteomics approach to examine the cardiotoxic effects of Nemopilema nomurai Jellyfish venom.
Heart Failure
Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat.
Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.
Hepatitis
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma.
Hepatitis B
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Hepatitis C
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Hepatitis C, Chronic
Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Hepatoblastoma
A human short-chain dehydrogenase/reductase gene: structure, chromosomal localization, tissue expression and subcellular localization of its product.
A nuclear protein, synthesized in growth-arrested human hepatoblastoma cells, is a novel member of the short-chain alcohol dehydrogenase family.
HIV Infections
Short-term feeding of baicalin inhibits age-associated NF-kappaB activation.
Huntington Disease
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Hyperalgesia
Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model.
Different effects of two aldose reductase inhibitors on nociception and prostaglandin E.
Effect of Tinospora cordifolia on experimental diabetic neuropathy.
Mechanical hyperalgesia in rat models of systemic and local hyperglycemia.
Pathogenesis of spinally mediated hyperalgesia in diabetes.
Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine.
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Hyperglycemia
A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat.
A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Activation of aldose reductase by nonenzymatic glycosylation.
Activation of aldose reductase from human tissues.
Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase.
Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats.
Aldose reductase and its inhibition in the control of diabetic complications.
Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals.
Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy.
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
Aldose reductase inhibition of a saponin-rich fraction and new furostanol saponin derivatives from Balanites aegyptiaca.
Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta.
Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells.
Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages.
Aldose reductase mediates the mitogenic signals of cytokines.
Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgf?1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice.
Anti-diabetic effects of Ganoderma lucidum.
Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?
Association study of sorbitol dehydrogenase -888G>C polymorphism with type 2 diabetic retinopathy in Caucasian-Brazilians.
Comparative study of peripheral neuropathy and nerve regeneration in NOD and ICR diabetic mice.
Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
Cytoprotective mechanism of action of curcumin against cataract.
Damage to the crystalline lens in infants of diabetic mothers: a pathology so far neglected?
Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase.
Diabetic kidney disease; review of the current knowledge.
Diabetic retinopathy and pregnancy.
Differential regulation of aldose reductase expression during macrophage polarization depends on hyperglycemia.
Early involvement of central nervous system in type I diabetic patients.
Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Effect of hyperglycemia on sorbitol and myo-inositol content of cultured rat conceptus: failure of aldose reductase inhibitors to modify myo-inositol depletion and dysmorphogenesis.
Effect of hyperglycemia on sorbitol and myo-inositol content of cultured rat conceptus: prevention of dysmorphogenesis with aldose reductase inhibitors and myo-inositol.
Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation.
Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.
Effects of high glucose concentrations and epalrestat on sorbitol and myo-inositol metabolism in cultured rabbit aortic smooth muscle cells.
Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes.
Effects of osmotic stress and hyperglycemia on aldose reductase gene expression in human renal proximal tubule cells.
Epalrestat prevents the decrease in gastric mucosal blood flow and protects the gastric mucosa in streptozotocin diabetic rats.
Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
Ethanol metabolism, cirrhosis and alcoholism.
Extraction and identification of three major aldose reductase inhibitors from Artemisia montana.
Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.
Glutathione depletion in the lens of galactosemic and diabetic rats.
Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells.
Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway.
Inhibition of phosphatidylinositol synthase by glucose in human retinal pigment epithelial cells.
Mechanism of capsaicin inhibition of aldose reductase activity.
New pharmacologic approaches to treating diabetic retinopathy.
NIH conference. Aldose reductase and complications of diabetes.
No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
Pathogenesis of diabetic nephropathy.
Pathogenesis of diabetic neuropathy--do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?
Pathological mechanisms involved in diabetic neuropathy: can we slow the process?
Permeability changes at blood-retinal barrier in diabetes and effect of aldose reductase inhibition.
Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.
Possible involvement of facilitated polyol pathway in augmentation of intimal hyperplasia in rabbits with alloxan-induced hyperglycemia.
Potential use of aldose reductase inhibitors to prevent diabetic complications.
Prophylactic role of arjunolic acid in response to streptozotocin mediated diabetic renal injury: activation of polyol pathway and oxidative stress responsive signaling cascades.
Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.
Reduction of basement membrane thickening in diabetic cat retina by sulindac.
Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract.
Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol.
Screening for and managing diabetic retinopathy: current approaches.
Semi-quantitation of mRNA by polymerase chain reaction. Levels of oxidative defense enzymes and aldose reductase in rat lenses cultured in hyperglycemic or oxidative medium.
The activity of aldose reductase is elevated in diabetic mouse heart.
The effect of insulin and aldose reductase inhibition on the phosphate metabolism of streptozotocin-diabetic rat lens.
The effect of oxidants on biomembranes and cellular metabolism.
The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes.
The effects of elevated glucose on Na+/K(+)-ATPase of cultured bovine retinal pigment epithelial cells measured by a new nonradioactive rubidium uptake assay.
The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat.
Time-dependent aspects of osmolyte changes in rat kidney, urine, blood and lens with sorbinil and galactose feeding.
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Transcriptome Profiles Using Next-Generation Sequencing Reveal Liver Changes in the Early Stage of Diabetes in Tree Shrew (Tupaia belangeri chinensis).
Uptake of myo-inositol by early-somite rat conceptus. Transport kinetics and effects of hyperglycemia.
Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
[Two forms of aldose reductase in erythrocytes from patients with insulin-dependent diabetes mellitus]
Hyperlipidemias
Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis.
Hypertension
Aldose reductase C-106T polymorphism is associated with the risk of essential hypertension.
Aldose reductase inhibitors zopolrestat and ferulic acid alleviate hypertension associated with diabetes: effect on vascular reactivity.
Fluorometric studies on the blood-retinal barrier in experimental animals.
Racial difference in aldose reductase C-106T genetic polymorphism and association with essential hypertension.
Hypertension, Pulmonary
Endotoxin causes pulmonary hypertension by upregulating smooth muscle endothelin type-B receptors: role of aldose reductase.
Hyperthyroidism
Thyroid hormone action on intermediary metabolism. Part III. Protein metabolism in hyper- and hypothyroidism.
Hypertriglyceridemia
Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.
Hypesthesia
Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats.
Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway.
Hypoglycemia
Aldose reductase inhibitory activity of compounds from Zea mays L.
Inhibition of aldose reductase by phenylethanoid glycoside isolated from the seeds of Paulownia coreana.
Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity.
Inhibitory effects of Zingiber officinale Roscoe derived components on aldose reductase activity in vitro and in vivo.
[Status of the monooxygenase enzyme system in rat and rabbit organs in sugar diabetes and upon insulin administration]
Hypotension, Orthostatic
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Infection
Bacteroides fragilis Enterotoxin Upregulates Intercellular Adhesion Molecule-1 in Endothelial Cells via an Aldose Reductase-, MAPK-, and NF-{kappa}B-Dependent Pathway, Leading to Monocyte Adhesion to Endothelial Cells.
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Drug metabolism in experimental tuberculosis: I. Changes in hepatic and pulmonary monooxygenase activities due to infection.
Identification of unique or elevated levels of kernel proteins in aflatoxin-resistant maize genotypes through proteome analysis.
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Infection of barley with the parasitic fungus Blumeria graminis f.sp. hordei results in the induction of HvADH1 and HvADH2.
Rat liver alcohol dehydrogenase isozymes: influence of infection with Trypanosoma.
RNAi knock-downs support roles for the mucin-like (AeIMUC1) gene and short-chain dehydrogenase/reductase (SDR) gene in Aedes aegypti susceptibility to Plasmodium gallinaceum.
Influenza, Human
QSAR models based on quantum topological molecular similarity.
Quantum topological QSAR models based on the MOLMAP approach.
Insulin Resistance
Effects of S-Allylcysteine on Biomarkers of the Polyol Pathway in Rats with Type 2 Diabetes.
Euonymus alatus: A Review on Its Phytochemistry and Antidiabetic Activity.
[The experimental study of Radix Puerariae inhibiting glycation in rats induced by D-galactose]
Keloid
The aldo-keto reductase AKR1B10 is upregulated in keloid epidermis, implicating retinoic acid pathway dysregulation in the pathogenesis of keloid disease.
Ketosis
The structures of Alcaligenes faecalis D-3-hydroxybutyrate dehydrogenase before and after NAD+ and acetate binding suggest a dynamical reaction mechanism as a member of the SDR family.
Kidney Diseases, Cystic
Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
Kidney Failure, Chronic
Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes.
l-iditol 2-dehydrogenase deficiency
Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency.
[Effects of transgenic human aldose reductase and sorbitol dehydrogenase deficiency on diabetes complications]
Leishmaniasis, Visceral
A glutathione-specific aldose reductase of Leishmania donovani and its potential implications for methylglyoxal detoxification pathway.
Leukemia
Characterization of daunorubicin resistance in K562 leukemia cells lacking daunorubicin reductase activity.
Daunorubicin reductase activity in leukemia leukocyte homogenates.
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
The monocytic differentiation of HL60 induced by rat kidney NADPH-linked high-Km aldehyde reductase protein.
Leukemia, Myeloid
NADPH-dependent reductases and polyol formation in human leukemia cell lines.
The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Leukemia, Myeloid, Acute
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.
Leukoplakia
Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex.
Liver Cirrhosis, Alcoholic
Alterations of liver alcohol dehydrogenase and other hepatic enzymes in alcoholic cirrhosis.
Polymorphism of alcohol dehydrogenase, alcohol and aldehyde dehydrogenase activities: implication in alcoholic cirrhosis in white patients. The French Group for Research on Alcohol and Liver.
Liver Diseases
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Genetic polymorphism of liver alcohol dehydrogenase in Spanish subjects: significance of alcohol consumption and liver disease.
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro.
Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage.
Liver Diseases, Alcoholic
Atypical liver alcohol dehydrogenase in the Spanish population: its relation with the development of alcoholic liver disease.
Liver Neoplasms
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Overexpression of aldose reductase in liver cancers may contribute to drug resistance.
Lung Neoplasms
Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Protective roles of aldo-keto reductase 1B10 and autophagy against toxicity induced by p-quinone metabolites of tert-butylhydroquinone in lung cancer A549 cells.
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Lymphoma, B-Cell
Overexpression of Aldose Reductase Render Mouse Hepatocytes More Sensitive to Acetaminophen Induced Oxidative Stress and Cell Death.
Melanoma
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI.
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma.
Melanoma, Experimental
Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.
Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI.
Mesothelioma
Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Metabolic Diseases
Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
Effect of the isoflavone genistein against galactose-induced cataracts in rats.
Microaneurysm
Amelioration of diabetes-like retinal changes in galactose-fed dogs.
Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.
Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175.
Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors.
Quantitative analysis of retinal vessel changes in galactose-fed dogs.
[What is the etiology of diabetic retinopathy?]
Mouth Neoplasms
Gedunin abrogates aldose reductase, PI3K/Akt/mToR, and NF-?B signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis.
Muscular Diseases
Polyol pathway-related skeletal muscle contractile and morphological abnormalities in diabetic rats.
Muscular Dystrophies
Chicken muscle aldose reductase: purification, properties and relationship to other chicken aldo/keto reductases.
Myocardial Infarction
Aldose reductase: a novel target for cardioprotective interventions.
Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins.
Myocardial Ischemia
Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury.
Myocardial Reperfusion Injury
Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism.
Neoplasm Metastasis
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Inhibition of aldose reductase prevents colon cancer metastasis.
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Neoplasms
A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
Accumulation and spatial location of aldose reductase mRNA in a lens tumor of an alpha A-crystallin/SV40 T antigen transgenic mouse line.
Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.
ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway.
AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo.
AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects.
Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells.
Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.
Ameliorative effects of thymoquinone against eye lens changes in streptozotocin diabetic rats.
Anti-diabetic potential of alkaloid rich fraction from Capparis decidua on diabetic mice.
Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-?B and MAPK pathways.
Cadherins as novel targets for anti-cancer therapy.
Cellular senescence bypass screen identifies new putative tumor suppressor genes.
Characterizing WW Domain Interactions of Tumor Suppressor WWOX Reveals Its Association with Multiprotein Networks.
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Cisplatin and platinum drugs at the molecular level. (Review).
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an "induced-fit" mechanism and a conserved basic motif involved in the binding of androgen.
Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors.
Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Diallyl sulfide protects against N-nitrosodiethylamine-induced liver tumorigenesis: role of aldose reductase.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes.
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition.
Establishment and characterization of mouse mammary carcinoma cell lines expressing RET with a multiple endocrine neoplasia 2A mutation.
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Gateways to clinical trials.
Genomic alterations in breast cancer patients in betel quid and non betel quid chewers.
Heat shock protein 90-? mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors.
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response.
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma.
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Inhibition of aldose reductase prevents colon cancer metastasis.
Inhibition of human aldose reductase-like protein (AKR1B10) by ?- and ?-mangostins, major components of pericarps of mangosteen.
Inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights.
Inhibitory effects of polyphenols isolated from Rhus verniciflua on Aldo-keto reductase family 1 B10.
Involvement of nuclear factor kappaB in up-regulation of aldose reductase gene expression by 12-O-tetradecanoylphorbol-13-acetate in HeLa cells.
Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Melphalan in regional chemotherapy for locally recurrent metastatic melanoma.
Metabolic characteristics and enflurane defluorination of cytochrome P450-dependent monooxygenases in human hepatocellular carcinoma.
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
N-cadherin as a therapeutic target in cancer.
N-cadherin in neuroblastoma disease: expression and clinical significance.
Novel aldose reductase inhibitors: a patent survey (2006--present).
Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha.
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer.
Overexpression of aldose reductase in human cancer tissues.
Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors.
Phenolic glycosides and other constituents from the bark of Magnolia officinalis.
Phorbol ester up-regulates aldose reductase expression in A549 cells: a potential role for aldose reductase in cell cycle modulation.
Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Prenatal alcohol exposure alters phosphorylation and glycosylation of proteins in rat offspring liver.
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma.
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Renal gene expression in embryonic and newborn diabetic mice.
Selective inhibition of human type-5 17?-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma.
SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity.
Stimulation of N-cadherin-dependent neurite outgrowth by small molecule peptide mimetic agonists of the N-cadherin HAV motif.
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Structural Determinants of the Selectivity of 3-Benzyluracil-1-acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10.
Studies on the alkaloids of the bark of Magnolia officinalis: isolation and on-line analysis by HPLC-ESI-MS(n).
Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
Targeting aldose reductase for the treatment of cancer.
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death.
Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Transcriptomic responses of cancerous and noncancerous human colon cells to sulforaphane and selenium.
Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex.
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity.
[Proteomic analysis of morphine rabbit myocardium with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry]
Neuralgia
Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives.
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
Phosphorylation of c-Jun N-terminal kinase (JNK) in sensory neurones of diabetic rats, with possible effects on nerve conduction and neuropathic pain: prevention with an aldose reductase inhibitor.
Neurilemmoma
Polyol pathway and protein kinase C activity of rat Schwannoma cells.
Neuroaxonal Dystrophies
Effect of sorbitol dehydrogenase inhibition on experimental diabetic autonomic neuropathy.
Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
Neuroblastoma
Cloning and expression of human aldose reductase.
Effect of fructose supplementation on sorbitol accumulation and myo-inositol metabolism in cultured neuroblastoma cells exposed to increased glucose concentrations.
Effect of increased glucose levels on Na+/K+-pump activity in cultured neuroblastoma cells.
Synthesis and catabolism of gamma-hydroxybutyrate in SH-SY5Y human neuroblastoma cells: role of the aldo-keto reductase AKR7A2.
Upregulation of cellular glutathione by 3H-1,2-dithiole-3-thione as a possible treatment strategy for protecting against acrolein-induced neurocytotoxicity.
Neuroendocrine Tumors
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Neurologic Manifestations
Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
Non-alcoholic Fatty Liver Disease
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor ?.
Obesity
Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE).
High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition.
[Aldehyde reductase activity and blood aldo-keto reductase spectrum in adolescents with neuroendocrine obesity].
Optic Nerve Diseases
Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process.
The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.
Ovarian Neoplasms
Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions.
Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer.
Pain
Anti-diabetic and anti-Alzheimer's disease activities of Angelica decursiva.
Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model.
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
Pancreatic Neoplasms
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
Parkinson Disease
Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson's disease.
Periodontitis
Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats.
Efficacy of Structurally-Diverse Aldose Reductase Inhibitors on Experimental Periodontitis in Rats.
Peripheral Nerve Injuries
Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model.
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.
Peripheral Nervous System Diseases
A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes.
Aldose reductase inhibition: studies with alrestatin.
Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.
Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report.
Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine.
Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
How does glucose generate oxidative stress in peripheral nerve?
Influence of long-term aldose reductase inhibitor therapy on autonomic dysfunction of urinary bladder, stomach and cardiovascular systems in diabetic patients.
Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
New pharmacologic approaches to treating diabetic retinopathy.
Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
Thoracic polyradiculopathy--abdominal wall swelling and sensory symptoms in diabetes mellitus.
WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
[Examination of questionnaire items regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of this disorder - influence on treatment course]
[Pharmacological effects of Gosha-jinki-gan-ryo extract: effects on experimental diabetes]
[Progress in research of aldose reductase inhibitors in traditional medicinal herbs]
[Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes]
[Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients]
Pneumonia
Novel role for aldose reductase in mediating acute inflammatory responses in the lung.
Polyneuropathies
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Diabetic neuropathy: pathogenesis and therapy.
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
[Diabetic neuropathy. Current concepts on etiopathogenesis, diagnosis, and treatment]
Polyradiculopathy
Thoracic polyradiculopathy--abdominal wall swelling and sensory symptoms in diabetes mellitus.
Potassium Deficiency
Potassium depletion modulates aldose reductase mRNA in rat renal inner medulla.
Pre-Eclampsia
Differential proteomic analysis of highly purified placental cytotrophoblasts in preeclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense.
Pressure Ulcer
Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy.
Prostatic Neoplasms
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-?-Hydroxysteroid Dehydrogenase AKR1C3.
A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer.
Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium.
PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3.
Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
Proteinuria
Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats.
Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
Functional and structural alterations of the glomerular permeability barrier in experimental galactosemia.
Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats.
The polyol pathway, sorbinil, and renal dysfunction.
Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus.
Pulmonary Fibrosis
Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat.
Renal Insufficiency
Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients.
Renal Insufficiency, Chronic
Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
Differential expression of proteins from cultured endothelial cells exposed to uremic versus normal serum.
Reperfusion Injury
Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore.
Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury.
Central role for aldose reductase pathway in myocardial ischemic injury.
Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.
Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina.
The Aldose Reductase Inhibitor Fidarestat Suppresses Ischemia-Reperfusion-Induced Inflammatory Response in Rat Retina.
The Inhibition of Aldose Reductase Attenuates Hepatic Ischemia-Reperfusion Injury Through Reducing Inflammatory Response.
Retinal Degeneration
[The NADP.H-cytochrome C reductase and aldose reductase activities in the retina, cerebral cortex and liver of healthy rats and of those with hereditary retinal degeneration in the early postnatal development period]
[The role of iron ions in regulating aldose reductase activity in the cerebral cortex and retina in health rats and rats with hereditary retinal degeneration]
Retinal Neovascularization
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Retinopathy of Prematurity
Deficiency of aldose reductase attenuates inner retinal neuronal changes in a mouse model of retinopathy of prematurity.
Rhinitis, Allergic
Prevention of Allergic Rhinitis by Aldose Reductase Inhibition in a Murine Model.
Riboflavin Deficiency
Effects of riboflavin deficiency on lipid peroxidation of rat liver microsomes.
Lipid metabolism in riboflavin-deficient rats. 2. Mitochondrial fatty acid oxidation and the microsomal desaturation pathway.
Sarcoma, Experimental
Purification and properties of aldose reductase and aldehyde reductase from EHS tumor cells.
Sarcoma, Yoshida
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Scabies
Production of the Streptomyces scabies coronafacoyl phytotoxins involves a novel biosynthetic pathway with an F420 -dependent oxidoreductase and a short-chain dehydrogenase/reductase.
Seizures
Diet composition, alcohol utilization, and dependence.
Sensation Disorders
Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
Sepsis
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis.
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition.
Novel aldose reductase inhibitors: a patent survey (2006--present).
Shock, Septic
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition.
Spinal Cord Injuries
Aldose Reductase Regulates Microglia/Macrophages Polarization Through the cAMP Response Element-Binding Protein After Spinal Cord Injury in Mice.
Stomach Neoplasms
Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
[Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].
Stroke
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Tardive Dyskinesia
Extrapyramidal disorders: a possible underlying mechanism.
Thiamine Deficiency
Acceleration of ethanol metabolism by past thiamine deficiency.
Thrombosis
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Thyroiditis
NADPH-dependent reductases in dog thyroid: comparison of a third enzyme "glyceraldehyde reductase" to dog thyroid aldehyde reductase.
Tongue Neoplasms
Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response.
Tuberculosis
Biotransformation and bioactivation reactions - 2015 literature highlights.
Drug metabolism in experimental tuberculosis: I. Changes in hepatic and pulmonary monooxygenase activities due to infection.
Uremia
Effect of uremia on rates of ethanol disappearance from the blood and on the activities of the ethanol-oxidizing enzymes.
Urinary Bladder Neoplasms
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells.
Urinary Bladder, Overactive
Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder.
Uterine Cervical Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Uterine Diseases
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases.
Uveitis
Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice.
Aldose reductase inhibition prevents endotoxin-induced uveitis in rats.
Amelioration of experimental autoimmune uveoretinitis by aldose reductase inhibition in Lewis rats.
Inhibition of ocular aldose reductase by a new benzofuroxane derivative ameliorates rat endotoxic uveitis.
Vascular System Injuries
[Epidemiology, pathogenesis and therapy of diabetic retinopathy and maculopathy]
Vasculitis
Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.
Virus Diseases
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Vision Disorders
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
Vitamin A Deficiency
Effects of vitamin A deficiency on rat liver alcohol dehydrogenase expression and alcohol elimination rate in rats.
Vitreous Hemorrhage
[Pathophysiology of diabetic retinopathy and nephropathy]